1. Home
  2. OCCI vs ANVS Comparison

OCCI vs ANVS Comparison

Compare OCCI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Credit Company Inc.

OCCI

OFS Credit Company Inc.

N/A

Current Price

$2.71

Market Cap

73.0M

Sector

Finance

ML Signal

N/A

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

N/A

Current Price

$1.73

Market Cap

76.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OCCI
ANVS
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.0M
76.6M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
OCCI
ANVS
Price
$2.71
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
197.1K
538.9K
Earning Date
12-11-2023
05-12-2026
Dividend Yield
24.32%
N/A
EPS Growth
N/A
39.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$1.54
52 Week High
$6.14
$5.50

Technical Indicators

Market Signals
Indicator
OCCI
ANVS
Relative Strength Index (RSI) 56.82 47.83
Support Level $2.62 $1.71
Resistance Level $2.67 $1.98
Average True Range (ATR) 0.07 0.09
MACD 0.02 -0.00
Stochastic Oscillator 86.96 20.59

Price Performance

Historical Comparison
OCCI
ANVS

About OCCI OFS Credit Company Inc.

OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: